“…278,297,299,311 The mechanisms of immunemodulation induced by FUS-assisted BBB opening have been comprehensively reviewed by Chen et al 312 PSMA is a cell-surface protein that is highly expressed in prostate cancer 313 and also in the endothelium of the tumour neovasculature of several solid tumours, 314 including GBM, 315-318 making it an excellent target for antibody-drug conjugates or peptide receptor radionuclide therapy. 315 Recently 68 Ga-PSMA-11 has also been shown to be a promising PET imaging agent for the diagnosis of patients with primary GBM 319 and for assessing tumour recurrence, 321,322 and as such, it has a great potential for treatment stratification purposes. 319 Modifications of the PSMA-11 peptide have resulted in the development of the small-molecule ligand PSMA-617, which has the advantage of being suitable for radiolabelling with different radioisotopes, including 68 Ga, 177 Lu,111 In and 90 Y, and thus, it can be used for both PET diagnostic imaging and radionuclide targeted therapy.…”